anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Pruritic dermatoses and sleep disorders have significant impacts on the health and quality of life of patients. Inflammatory conditions may lead to the sensation of itching. This study was to evaluate the association between pruritic dermatoses and inflammatory factors on sleep disorders. Data in the cross-sectional study were extracted from the National Health and Nutrition Examination Survey. The study population was divided into participants with and without sleep disorders. Pruritic dermatoses were assessed by the participant's self-report. Inflammatory factors included white blood cell count (WBC), lymphocyte count (LYM) and prognostic nutritional index (PNI). Logistic regression models were used with odds ratios and confidence intervals. The attributable proportion of interaction (AP) was utilized to assess the interaction between pruritic dermatoses and inflammatory factors on sleep disorders. Totally, 3,520 participants were included and 214 (6.08%) had sleep disorders. Pruritic dermatoses were associated with sleep disorders after adjusting for gender, age, race, marital status, body mass index, drinking, smoking, asthma, hay fever, allergy, depression and caffeine. LYM was associated with sleep disorders when inflammatory factors were divided by median. The interaction between participants without pruritic dermatoses and PNI < median on sleep disorders was observed compared to participants without pruritic dermatoses and PNI > median. Pruritic dermatoses were significantly associated with sleep disorders. We also found that a high level of PNI had an enhanced effect on the relationship between pruritic dermatoses and sleep disorders. Clinicians should focus on the potential sleep-related risks and changes in inflammatory factors in patients with pruritic dermatoses and intervene in time.
Subjects with moderate to severe renal impairment equivalent to National Kidney Foundation Kidney Disease Outcomes Quality Initiative stage 3 and stage 4 who are not undergoing dialysis will be included. Subjects will receive single 50 mg and 150 mg oral doses of GSK1278863A across two dosing periods in a single-blind, randomized sequence. Doses of GSK1278863A will be given as 25 mg and 100 mg tablets, with matching placebo tablets to maintain treatment blinding.
<P>PROBLEM TO BE SOLVED: To provide a spray device which contains a composition for simultaneously imparting multiple local irritation.  <P>SOLUTION: The spray device contains a water-based nonflammable composition with a viscosity of 0.2 to 30 mPa. s at 20°C. The device simultaneously and locally imparts each irritation by heat and mechanical kinetic energy for cooling a skin or a body tissue and for generating pulse in a body, so that the device is composed so as to emit a low-temperature water-based particle at 0.1 to 8 gm/sec. and at an angle of 0 to 145 degrees at 20°C under a pressure of 0.5 to 11 bar generated by using dimethyl ether, LP gas or their mixture at 20°C. The water-based particle has a temperature higher than 0°C and lower than the surrounding temperature and has a diameter of 10 to 600 micron.  <P>COPYRIGHT: (C)2007,JPO&INPIT
In the past few years, physicians have been proposing that an emergency department visit may act as a "teachable moment" and emergency medicine physicians should educate families about injury prevention. With an epidemic number of injuries occurring, every health care provider should play some role in combating the problem. However, emergency departments can be busy and overcrowded, making it difficult for staff, in a cost efficient manner, to be able to provide families with the appropriate injury prevention information. Kiosks have been shown to be effective in a pediatric emergency department setting to determine the needs of families and to educate them about safety practices. Thus, computerized kiosks may offer a more cost effective alternative to educating families, compared to a staff member, about injury prevention in the emergency medicine setting and they would have the ability to reach more individuals during the non-high peak emergency department hours which are difficult to staff. Also, a computerized kiosk may be more effective in eliciting a behavior change than a staff person as families may be inclined to answer more freely when asked questions anonymously, allowing them to receive more detailed safety information. In addition, the kiosk provides direct recommendations about behavior changes based on parental responses in a very short time period. Typically, families only hear about a few behavior change recommendations when discussing with an injury prevention staff person in an emergency department setting due to time constraints and family interest. With more directed injury prevention information and detailed recommendations on behavior changes in a cost efficient manner, kiosks may prove to be more effective in having families practice safer behaviors after leaving the pediatric emergency department.

This is a comparative study performed in the emergency department of a level 1 pediatric trauma center during the normal business hours of the Safety Resource Center. Families entering the pediatric emergency department for care will be randomized on specific days of the week to receive IP information from an IP specialist or from a computerized kiosk in the waiting room. A twenty day block random numbers table will be used to determine which days families entering the ED will utilize the computerized kiosk and which days they will be screened by clinical research assistants (CRCs) and provided with safety instructions by an IP specialist.
Penetrating injuries comprise roughly 30% of Methodist Health System (MHS) trauma patients. Firearm-related events have become more prevalent in the past few years . Active shooter events, mass casualties, assaults, and homicide are more commonplace which leads to an increase of trauma patients needing management of penetrating injuries. On average, penetrating traumas only make up 14% of comparable center patient volumes. In spring 2022, we also were ranked 3/10 for our penetrating trauma outcomes with lower than expected mortality (TQIP Benchmarking Report). Together, as a Level 1 trauma center with above average penetrating injury volume we must take efforts to best understand the opportunities for our patients and disseminate those observations to the trauma community
Prostate cancer (PCa) is a prevalent malignant neoplasm affecting the male reproductive system globally. However, the diagnostic and therapeutic approaches fall short of meeting the demands posed by PCa. Poor expression of miRNA-203 (miR-203) within PCa tissues and cells implies its potential utility as a diagnostic indicator for PCa. Exosomes (Exo), membranous vesicles released by various cells, are rich reservoirs of miRNAs. However, the presence of miR-203 presents within Exo derived from PCa cells remains unclarified. In this study, Exo was isolated from urine specimens collected from clinical PCa patients and LNCaP cells to detect miR-203 expression. Meanwhile, the impact of overexpressed miR-203 on M0 macrophages (mø) was analyzed. Subsequently, alterations in the proliferative, migratory, and invasive capacities of LNCaP cells were examined within a co-culture system featuring elevated miR-203 levels in both macrophages and LNCaP cells. Furthermore, the repercussions of miR-203 upregulation or inhibition were explored in a murine PCa tumor model. The results revealed that Exo manifested a circular or elliptical morphology, encapsulating a phospholipid bilayer approximately 100 nm in diameter. Notably, Exo readily infiltrated, with both Exo and miR-203-overexpressing Exo prompting macrophage polarization toward the M1 subtype. In the co-culture system, miR-203 exhibited pronounced suppression of LNCaP cell proliferation, migration, and invasion, while concurrently fostering apoptosis as compared with the LNCaP group (Control). In vivo experiments further disclosed that miR-203 greatly inhibited the growth of PCa tumors in nude mice. Markedly heightened expression of M1 macrophage markers such as IL-1β, IL-6, IL-12, CXCL9, and CXCL10 was observed within the tumor microenvironment following miR-203 intervention, as opposed to the model group. However, the introduction of miR-203 antagomir led to a reversal in tumor growth trends. This investigation indicates the presence of miR-203 within the urine of PCa patients and Exo originating from cells, and that miR-203 exerted antitumor effect by facilitating M1 macrophage polarization. Our study furnishes valuable insights into the potential applicability of miR-203 as a diagnostic biomarker and therapeutic target for PCa.
The use of lidocaine as a local anesthetic is a common and widely used in practice. Lidocaine patches can be used for localized pain control and can be placed every 24 hours. The use of lidocaine patches in post-operative patients has been reported in one case report in obstetric literature. There is one study that reports decreased immediate postoperative pain when lidocaine patches were placed at laparoscopic port sites following gynecologic surgery as measured by visual analog scale score and the Prince Henry and 5-point verbal rating pain scale. There have been no studies looking at the impact of lidocaine patches in obstetric surgical procedures, specifically cesarean sections.

Cesarean sections are one of the most common surgeries in the United States. Following cesarean sections it is common to utilize opioids in the hospital and upon discharge to manage patient's post-operative pain. According to the CDC overdose deaths involving prescription opioids were five times higher in 2017 than in 1999 with over 200,000 deaths. This creates an opportunity to decrease the use of post-operative opioids with the application of a lidocaine patch as an adjunctive post-operative pain management modality following cesarean sections.

Lidocaine patches are a common topical analgesia therapy used for localized pain control in the inpatient and outpatient setting. It's use in the postoperative period is less understood and the use of topical lidocaine patches has not been thoroughly investigated in the surgical literature. Thus far, it has been shown as an effective therapy at laparoscopic port sites following laparoscopic appendectomies. It's use in obstetrical surgeries has not been studied. Overall, the limited research on this topic making it a valuable area of research.

This study will involve prospective enrollment of women undergoing cesarean deliveries. Women will be randomized to receive a lidocaine patch or no lidocaine patch to be worn for 72 hours after delivery to help manage postoperative pain. This will be an adjunctive therapy in addition to the parental and oral narcotic pain medication that is routine prescribed. The utility of lidocaine patches for management of post-cesarean delivery pain will be assess by 2 measures. The first measure will involve the total daily dose of narcotic used in morphine equivalent doses. The second outcome assessed will be subjective pain as measured on a 1-10 scale and reported by the patients to nursing staff. This score will be averaged for each 24 hour period post-operatively.
The invention provides a coxsackievirus A16-type virus strain and a use thereof. The coxsackievirus A16-type virus strain has the preservation number of CGMCC No. 5371. The full-length sequence analysis and the mass spectrometry analysis on a VP1 protein produced by the coxsackievirus A16-type virus strain prove that the oxsackievirus A16-type virus strain is a good CA16 virus strain which is not polluted by allothigenes and has good immunogenicity. The CA16 virus strain can efficiently proliferate in Vero cells and has virus titer of 7.41g CCID 50/ml. The CA16 virus strain or a vaccine prepared from the CA16 virus strain can be used for preventing diseases caused by CA16 viruses, and has the characteristics of stable titer, good immunogenicity and less immunizing dose.
The aim of this study was to compare oxytocin receptor (OXTR) immunoreactivity in placentas obtained from women having cesarean and natural birth. The study samples consisted of placentas of 32 mothers who had 16 natural birth (control) and 16 cesarean (case) birth in Kars Harakani State Hospital and Kafkas University Health Research and Application Hospital. At the beginning of the study, 40 placentas obtained in total, 5 were not included in the study due to mismatched blood, 2 were not included in the study after the chronic disease (thyroid, Behçet's disease) detected, and 1 was not included in the study due to the presence of accessory placenta. The means of binary variables were determined by applying the Independent Two-Sample T-Test. Pearson Correlation analysis was used to examine the relationship between the variables. Periodic acid-Schiff staining, H\&E and Triple staining techniques were applied to tissue samples obtained from placentas for histological examination. OXTR primary antibody was used for immunohistochemical examination. There was no significant difference between the groups in terms of histological examination. In the study, it was found that OXTR immunoreactivity was strong in decidual cells and stromal cells in villi. A stronger OXTR immunoreactivity was detected in villous stroma of placenta of the natural birth group compared to the cesarean birth group. Reaction was not observed in syncytotrophoblast cells and syncytial nodes in both groups, but strong immunoreaction was observed fetal endothelial cells and fetal capillaries in both groups. As a result, it is thought that the placenta pathology should be made routine for every birth because it gives information about the offspring.
This invention provides novel peptides that function in vivo as agonists of the VPAC2 receptor. These insulin secretagogue polypeptides are shown to lower blood glucose in vivo upon glucose challenge. The polypeptides of this invention are also stable in formulation and have long half-lives. The peptides of the present invention provide a therapy for patients with decreased endogenous insulin secretion, for example, type 2 diabetics. The invention is also directed to a method of treating a metabolic disease in a mammal comprising administering a therapeutically effective amount of the peptides to said mammal. ® KIPO & WIPO 2007
PROBLEM TO BE SOLVED: To obtain the subject new compound having an aryloxyacetyl group as a modifying group bonding to a terminal amino group, exhibiting excellent human immunodeficient virus protease-inhibitory activity and useful as an anti- AIDS agent. SOLUTION: This compound is expressed by the formula I (A is OCH2 CO; R1 to R5 are each H, amino, etc.; R6 is a bivalent hydrocarbon group forming a 5 to 7-membered ring together with bonding N atom and C atom or a bivalent group produced by substituting the C atom bonded to the bivalent hydrocarbon group with a hetero atom; R, is a univalent group derived from a 1-6C aliphatic hydrocarbon or a monocyclic aromatic hydrocarbon group having a total carbon number of <=12), e.g. (R)-N-t-butyl-3-[(2S,3S)-2-hydroxy-3[phenoxyacetyl] amino-4- phenylbutanoyl]-1,3thiazolidine-4-carboxamide. The compound can be produced by reacting an intermediate of the formula II with an activated derivative of a carboxylic acid of the formula III (Y is a group derived from an acid anhydride, etc.).
PURPOSE: A composition containing an miRNA inhibitor for preventing or treating solid cancer is provided to reduce generation of miRNA and suppress proliferation of solid cells. CONSTITUTION: A composition for preventing or treating cervical cancer contains anti-miRNA-199a. The anti-miRNA-199a is an oligonucleotide which has complementary sequence with 15 or more nucleotide sequence of miR-199a. The anti-miR-199a oligonucleotide has a nucleotide sequence of sequence number 2. A method for determining cervical cancer comprises: a step of measuring generation of miR-199a of a sample from a patient; a step of comparing the miR-199a generation between a healthy person and patient; and a step of determining cervical cancer when the generation level of the patient is higher than that of patient. The patient is mammal, and the sample is endocervical epithelial tissue or cell.
The present invention relates to a polynucleotide comprising a ubiquitous chromatin opening element (UCOE) which is not derived from 13. The polynucleotide of any one of claims 1 to 7, wherein the UCOE comprises the sequence of FIG. 20 between nucleotides 1 to 7627 or a functional homologue or fragment thereof. an LCR. The present invention also relates to a vector comprising the polynucleotide sequence, a host cell comprising the vector, use of the polynucleotide, vector or host cell in therapy and in an assay, and a method of identifying UCOEs. The UCOE opens chromatin or maintains chromatin in an open state and facilitates reproducible expression of an operably-linked gene in cells of at least two different tissue types.
This study is mainly based on a registry of 2000 consecutive patients with acute coronary syndrome who received invasive treatment and for whom platelet reactivity after clopidogrel treatment will be prospectively assessed.

In the acute phase, blood samples for platelet reactivity assessment will be obtained 12 to 18 hours from 600 mg clopidogrel loading. Platelet-rich plasma, obtained by centrifuging whole blood for 10 min at 200 g, was stimulated with 10 M adenosine 5'-diphosphate (ADP) and residual aggregation will be assessed using a APACT 4 light transmittance aggregometer. Platelet aggregation (according to the Born's method) will be evaluated considering the maximal percentage of platelet aggregation in response to stimulus. Patients with platelet aggregation by 10 µmol ADP ≥ 90th percentile of controls (70%) will be defined as non-responders. The assessment of platelet reactivity will be repeated at 6 months. The importance of concomitant aspirin resistance will be also evaluated in such of patients.
Prescription opioid abuse has been increasing dramatically in recent years. There is growing concern regarding the unprecedented increase in morbidity and mortality related to the use of opioids.1-2 In 2010 the rates of opioid sales, deaths, as well as associated treatment admissions have increased to more than triple the rates in 1999.1-2 Although policy makers and the media often associate the opioid crisis as a problem of nonmedical opioid abuse, evidence has suggested that opioid addiction occurs in both medical and nonmedical users.2 The Centers for Disease control and Prevention reported and warned that long-term opioid use often starts with treatment of some type of acute pain.3 Prescription opioids have been shown to be favorable in perioperative pain management, however, their effectiveness in chronic pain management is not as clear. Surgeons are among the highest opioid prescribers. Many common elective as well as trauma-related procedures have been reported as possible causes of increased prolonged opioid usage. Recent evidence also suggested that a considerable number of patients who were prescribed opioids struggle to with transitioning to non-opioid pain medications.1-6 Numerous methods have been considered and explored in effort of decreasing the misuse and abuse of prescription opioids. One of the methods being opioid counseling, in which patients are educated on the effects and risks of short-term and long-term opioid usage and physicians recommend and discuss the appropriate opioid usage as well as alternative nonopioid options. It has also been indicated that counseling is more effective if given earlier on in the patient's surgical care rather than through rushed education overview at discharge.1,4-6 Therefore, the purpose of this study is to evaluate the effect of perioperative opioid counseling within a specific group of patient population who are undergoing bilateral reduction mammoplasty.
PURPOSE:Cosmetic providing improved refreshing feeling with a small amount of a carbonic acid gas or a carbonic aicd gas-evolving substance blended, obtained by mixing a refrigerant-containing cosmetic composition with the carbonic acid gas or the carbonic acid gas-evolving substance. CONSTITUTION:A refrigerant-containing cosmetic composition is blended with a carbonic acid gas or a carbonic acid gas-evolving substance having vasodilating action. An amount of the refrigerant blended is preferably 0.001-5wt%, and that of the carbonic acid gas is preferably >=60ppm. The refrigerant-containing cosmetic composition is put in a pressure container, a high-pressure gas carbonic acid gas is introduced into it, or a carbonic acid gas-evolving source such as dry ice, etc. is added to the container, and it is closed. The cosmetic is applied by a method such as jetting contenst in use, supporting a carbonate and an acid in the absence of water on a carrier such as nonwoven fabric, cloth, etc., supporting the refrigerant-containing cosmetic composition together, applying it to the affected part to be coated in use, followed by supplying water to it so that a carbonic acid gas is evolved.
Sepsis is a life-threatening condition and usually be treated with antibiotics, which however often has severe side effects. This work proposed a novel Chinese traditional medicine JINHONG (JH) decoction for therapy of sepsis. We first identified the chemical constituents of JH decoction by using high-performance liquid chromatography and mass spectrometry (HPLC-MS). Then, we constructed a model mouse for sepsis by using cecal ligation and puncture (CLP). Metagenomic sequencing method was used to compare the diversity and abundance of the gut microbiota between normal, disease model, JH decoction-treatment and antibiotic-treatment mice. Many indices including the number of platelets, CD62p and CD63 content, AQP2 and AQP8 level, as well as the expression level of protein C confirmed that the sepsis resulted in serious pathological damage, while all of these indices could be reversed by JH decoction and antibiotics. The diversity and abundance of intestinal flora decreased in CLP mice, and the decrements aggravated after antibiotic treatment while can be recovered by JH decoction treatment. The abundance of anti-inflammatory Ruminococcaceae increased after JH decoction treatment, indicating that JH decoction could ameliorate pathology associated with sepsis in CLP model via modulating the intestinal flora. This study demonstrates that JH decoction could treat sepsis clinically without obvious adverse effects on gut microbiota.
The invention disclosed herein provides compositions and methods of treating cancer and other diseases related to activated immune cells using modulators of the TREM-1/DAP-12 signaling pathway. The compositions, including peptides and peptide variants, modulate TREM- 1 -mediated immunological response as standalone and combination-therapy treatment regimen. Further, methods are provided for predicting the efficacy of TREM-l modulatory therapies in patients. In one embodiment, the present invention relates to targeted treatment, prevention and/or detection of cancer including but not limited to lung cancer including non-small cell lung cancer, pancreatic cancer, giant cell tumor of the tendon sheath, tenosynovial giant cell tumor, pigmented villonodular synovitis, cancer cachexia, etc., and other cancers associated with myeloid cell activation and recruitment. Additionally, the present invention relates to the targeted treatment, prevention and/or detection of scleroderma including but not limited to calcinosis, Raynaud's phenomenon, esophageal dysmotility, scleroderma, or telangiectasia syndrome (CREST). The invention further relates to personalized medical treatments.